Medical Devices
GeoVax Explores Needle-Free Vaccine Delivery with Vaxxas Technology
GeoVax Labs, Inc. initiates a research program to evaluate the potential of a needle-free, self-administered GEO-MVA vaccine using Vaxxas' HD-MAP technology, aiming to enhance global immunization efforts.
Roth Capital Partners Facilitates CapsoVision's $27.5 Million IPO
CapsoVision, Inc. successfully launched its initial public offering with Roth Capital Partners as joint book-running manager, marking a significant milestone for the AI-powered medical technology sector.
HeartBeam Inc. Honored with 2025 Innovation Award for Pioneering Remote Cardiac Diagnostics
HeartBeam Inc. (NASDAQ: BEAT) has been awarded the 2025 Innovation Award in Remote Cardiac Diagnostics for its FDA-cleared 3D ECG technology, marking a significant advancement in non-clinical cardiac care.
Shoulder Innovations Secures $40 Million in Financing to Advance Shoulder Surgical Care
Shoulder Innovations has closed a $40 million convertible notes financing to further commercialize its advanced implant systems for shoulder arthroplasty, aiming to improve surgical outcomes and efficiency.
Diopter Technologies Advances Ocular Disease Treatment with Dissolving Contact Lens
Diopter Technologies has completed early clinical studies for a dissolving amniotic membrane biopolymer contact lens, offering a novel approach to treating ocular surface diseases by delivering growth factors directly to the eye.
Lorati's Nano-Emulsion Offers New Hope for Stroke Recovery
Lorati Co., Ltd. introduces a natural, mineral-based nano-emulsion therapy that promises a non-invasive solution for full recovery from both hemorrhagic and ischemic strokes, marking a significant advancement in stroke treatment.
SeaStar Medical's QUELIMMUNE Recognized by National Kidney Foundation for Innovation in Pediatric AKI Treatment
SeaStar Medical's QUELIMMUNE device, designed to treat pediatric acute kidney injury, has been awarded the 2025 Corporate Innovator Award by the National Kidney Foundation, highlighting its potential to significantly reduce mortality rates and improve quality of life for affected children.
Intelligent Bio Solutions Inc. to Showcase Fingerprint Sweat PK Study at ADLM 2025 Clinical Lab Expo
Intelligent Bio Solutions Inc. will present its pharmacokinetic study data at the ADLM 2025 Clinical Lab Expo, highlighting the reliability of fingerprint sweat as a non-invasive diagnostic tool for drug screening.
Somnair Secures $4.3M Seed Funding for Innovative Sleep Apnea Device
Somnair, founded by Johns Hopkins alumni, has raised $4.3 million to develop a non-invasive device for obstructive sleep apnea, addressing a significant unmet need for patients intolerant to traditional CPAP therapy.
HeartBeam Inc. (NASDAQ: BEAT) Pioneers At-Home Cardiac Care with Innovative ECG Technology
HeartBeam Inc. is revolutionizing cardiac care with its at-home detection and monitoring technology, offering a potential shift in how cardiac conditions are managed outside traditional medical settings.
Plexāā Secures $4.5 Million to Launch Innovative Breast Surgery Device in the U.S.
Plexāā's recent funding extension underscores the potential of its BLOOM⁴³ device to revolutionize breast surgery outcomes by reducing complications through Supraphysiological Preconditioning.
MS Tech Secures $1.2M R&D Grant for Early Disease Detection Biosensors
MS Tech Ltd. has been awarded a $1.2M R&D grant by the Israel Innovation Authority to advance its innovative biosensor technology for early disease screening and biomarkers diagnostics, marking a significant step forward in point-of-care diagnostics.
Prosidio Endoscope Facilitates Historic Endoscopic Pituitary Surgery in The Gambia
The first-ever endoscopic pituitary surgery in The Gambia, enabled by Prosidio's advanced endoscope, marks a significant advancement in neurosurgical care for the region.
SeaStar Medical's QUELIMMUNE Shows Promise in Treating Pediatric AKI
SeaStar Medical's QUELIMMUNE device, approved by the FDA, significantly reduces mortality rates in pediatric patients with acute kidney injury (AKI) by targeting the cytokine storm at its source.
SeaStar's QUELIMMUNE Shows Promise in Halving Pediatric Sepsis Mortality Rates
SeaStar Medical's QUELIMMUNE therapy, approved by the FDA in 2024, has demonstrated the potential to reduce pediatric sepsis mortality rates by half, offering hope for critically ill children with acute kidney injury.
Medicus Pharma Ltd. Develops Novel Non-Invasive Treatment for Basal Cell Carcinoma
Medicus Pharma Ltd. is advancing a revolutionary, non-invasive microneedle patch treatment for basal cell carcinoma, potentially transforming the $15 billion skin cancer treatment market.
HeartBeam Inc. to Showcase Innovations at iAccess Alpha Virtual Summer Conference
HeartBeam Inc. (NASDAQ: BEAT) will present its advancements in personalized cardiac care at the iAccess Alpha Virtual Best Ideas Summer Conference, highlighting its potential to redefine cardiac health management.
HeartBeam Inc. Receives FDA Clearance for Innovative Cable-Free ECG System
HeartBeam Inc. has achieved FDA 510(k) clearance for its pioneering, credit card-sized, cable-free ECG system, enhancing remote arrhythmia detection and cardiac care accessibility.
HeartBeam Inc. Strengthens Cardiac Care Innovation with New Patents
HeartBeam Inc. has secured two new U.S. patents for its 3D ECG and cardiac monitoring technology, marking a significant advancement in remote cardiac diagnostics and enhancing the company's intellectual property portfolio.
PolyPid Secures $26.7 Million Funding, Advances Toward FDA Approval with Promising D-PLEX₁₀₀
PolyPid Ltd. has secured $26.7 million in funding following successful Phase 3 trial results for its surgical infection prevention technology, D-PLEX₁₀₀, positioning the company for FDA approval and significant market impact.
HeartBeam Inc. Advances Cardiac Monitoring with New Patents
HeartBeam Inc. has secured two new U.S. patents for its innovative 3D ECG and cardiac monitoring technologies, marking a significant step forward in remote cardiac diagnostics and patient care.
HeartBeam Inc. and AccurKardia Collaborate to Enhance Remote Cardiac Monitoring
HeartBeam Inc. partners with AccurKardia to integrate FDA-cleared ECG analysis software into its portable cardiac monitoring device, aiming to improve arrhythmia detection and patient care accessibility.
HeartBeam Inc. Pioneers Cable-Free ECG System for At-Home Cardiac Monitoring
HeartBeam Inc. introduces a revolutionary cable-free system for synthesizing 12-lead ECGs from 3D signals, enabling patients to record their symptoms anywhere, potentially transforming cardiac care by facilitating early detection and timely intervention.
HeartBeam Inc.'s VALID-ECG Study Confirms High Diagnostic Accuracy of Synthesized 12-Lead ECG
HeartBeam Inc.'s innovative credit card-sized ECG device has shown a 93.4% diagnostic agreement with standard ECGs in the VALID-ECG study, marking a significant step towards portable cardiac care solutions.
HeartBeam Inc. Advances Toward Commercialization with Promising Q1 2025 Results
HeartBeam Inc. reports significant progress in its Q1 2025 results, including successful clinical endpoints in its VALID-ECG study and strategic collaborations, marking a pivotal step towards the commercialization of its innovative cardiac care technology.
HIGHER Corporation Recognized as 'Baby Unicorn' for Innovative Medical Devices
HIGHER Corporation's selection as a 'Baby Unicorn' underscores its potential in the global medical device market, with its HILO WAVE® product leading the charge in innovative skin regeneration technology.
Glucotrack Innovates Diabetes Management with Implantable Glucose Monitor
Glucotrack Inc. is revolutionizing diabetes care with its fully implantable continuous blood glucose monitoring system, addressing key patient concerns and setting new standards for accuracy and convenience.
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology
Nutriband Inc. has been granted a U.S. patent for its Aversa(TM) technology, marking a significant step forward in the fight against drug abuse and misuse with its abuse-deterrent transdermal products.
United Health Products Awaits FDA Decision on Hemostatic Gauze Clinical Study
United Health Products, Inc. is in the process of addressing FDA findings related to a BIMO audit for its hemostatic gauze product, CelluSTAT, aiming to expedite patient enrollment upon approval.
Nutriband Inc. Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
Nutriband Inc. is pioneering a novel transdermal delivery system for buprenorphine, aiming to address the opioid epidemic with safer treatment options, potentially revolutionizing pain and addiction therapies.